Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma

Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca and approximately 400 positions in 14 European countries. In the contemplated transaction, Galapagos will receive a €50 million upfront, potential milestone payments […]